Tourmaline Bio Q2 net loss $0.90/shr; positive Phase 2 TRANQUILITY data for pacibekitug

Tourmaline Bio, Inc.

2025-Q2 EPS reported -$1.79

Net loss of $23.1M ($0.90 per share) vs $17.5M ($0.68) in Q2 2024; R&D expense $19.6M.
Cash, equivalents, investments $256.4M as of June 30, 2025; runway into H2 2027.
Phase 2 TRANQUILITY trial showed >85% hs-CRP reduction with quarterly dosing of pacibekitug.
Planning Phase 3 cardiovascular outcomes trial in ASCVD; Phase 2 AAA trial to start H2 2025.
Additional TRANQUILITY data to be presented at ESC Congress Aug 31, 2025.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.